Aspire Biopharma Holdings, Inc. (ASBP): Entry into a Material Definitive Agreement
Aspire Biopharma Holdings, Inc. (ASBP) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.3 3 ex10-3.htm EX-10.3 Exhibit 10.3 SECURED CONVERTIBLE PROMISSORY NOTE PURCHASE AGREEMENT THIS SECURED CONVERTIBLE PROMISSORY NOTE PURCHASE AGREEMENT (this “ Agreement ”), dated as of August 6, 2026, is entered into by and among Aspire Biopharma Holdings, Inc., a Delaware
How this was made
The 30-second read
Why it matters
Convertible note financings typically introduce equity dilution risk and can weigh on valuation, especially when conversion is tied to an event of default. Traders should focus on conversion mechanics, security/collateral, and any protective covenants that affect downside scenarios.
Market read
New, primary-source financing terms were disclosed today, creating an immediate catalyst for dilution and credit-risk repricing.
What to watch
Key missing terms in the excerpt (maturity, conversion price/discount, investor concentration, covenants, and use of proceeds) can materially change dilution and default probability, so traders should verify the full exhibit and schedules.
Background
The 8-K reports entry into a material definitive agreement and includes an exhibit for a secured convertible promissory note purchase agreement dated Aug 6, 2026.
Ticker impact
Aspire Biopharma disclosed a secured convertible promissory note purchase agreement, including $3.0M purchase price and $3.75M principal with 20% OID.
Likely negative-to-neutral for the stock on financing overhang, with volatility driven by conversion terms and default risk.
8-K Item 1.01 and the exhibit describe the capital raise mechanics (OID, principal vs purchase price, conversion upon default). The excerpt does not provide proceeds use, maturity, or conversion discount, limiting precision on magnitude.
Market effects
Adds to the broader biotech financing backdrop where convertible structures can pressure equity valuations via dilution and default optionality.
Primarily impacts US small-cap biotech sentiment and liquidity.
Limited spillover beyond the company’s capital markets access.
Counterpoint
If the notes are small relative to cash needs and conversion is unlikely, the market may over-discount dilution risk and the stock could stabilize after initial selloff.
Key entities
- issuerAspire Biopharma Holdings, Inc.
Company entering the secured convertible promissory note purchase agreement disclosed in the 8-K.
- counterpartiesInvestors (Schedule 1)
Purchasers of the convertible notes under Rule 506(b) unregistered sales.
